A Phase II-study (Therapeutic Exploratory) of GAD-alum in Newly Diagnosed Type-1 Diabetic Patients, With Focus One the Presence of Viruses at the Time of Diagnosis.

Trial Profile

A Phase II-study (Therapeutic Exploratory) of GAD-alum in Newly Diagnosed Type-1 Diabetic Patients, With Focus One the Presence of Viruses at the Time of Diagnosis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms DiViD
  • Most Recent Events

    • 26 Apr 2011 Actual initiation date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 26 Apr 2011 Planned end date changed from 1 Aug 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
    • 26 Apr 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top